Suppr超能文献

抑制人多形核白细胞中的磷酸二酯酶IV及细胞内钙水平。

Inhibition of phosphodiesterase IV and intracellular calcium levels in human polymorphonuclear leukocytes.

作者信息

Villagrasa V, Navarrete C, Sanz C, Berto L, Perpiñá M, Cortijo J, Morcillo E J

机构信息

Department of Pharmacology, Faculty of Medicine and Odontology, University of Valencia, Spain.

出版信息

Methods Find Exp Clin Pharmacol. 1996 May;18(4):239-45.

PMID:8803956
Abstract

Phosphodiesterase (PDE) isoenzyme type IV is the predominant cyclic AMP hydrolytic activity in polymorphonuclear leukocytes (PMNs). PDE IV inhibitors depress functional responses of PMNs but their influence on intracellular calcium concentration ([Ca2+]i) has not been extensively studied. The present study examined the effects of rolipram (a selective PDE IV inhibitor) on the chemotactic peptide formyl-methionyl-leucyl-phenylalanine (fMLP)-induced changes of [Ca2+]i in fura-2 loaded human PMNs. Rolipram (1 nM-10 microM) did not alter basal [Ca2+]i values. fMLP (10 nM approximately EC50) produced a transient calcium response, i.e., a peak followed by decay to a residual value above baseline. Peak [Ca2+]i values after fMLP were not altered but a faster decay and a lower residual [Ca2+]i were observed in rolipram (0.1-10 microM)-treated cells. fMLP added after thimerosal (20 microM) produced a peak followed by a sustained oscillatory response. Rolipram (up to 10 microM) did not alter the peak but inhibited the sustained response (-log IC50 = 6.39 +/- 0.12). The inhibitory effects of rolipram may be due to alterations in the mobilization of Ca2+ produced by the increase in the cellular content of cyclic AMP. SKF94120 (a selective PDE III inhibitor) produced minor effects on the fMLP-induced calcium response. SCA40 (a mixed PDE III/IV/V inhibitor) produced similar effects but was less potent than rolipram. Reduction of the calcium response probably underlies the inhibition of PMN functions produced by PDE IV inhibitors.

摘要

磷酸二酯酶(PDE)IV型同工酶是多形核白细胞(PMN)中主要的环磷酸腺苷水解活性酶。PDE IV抑制剂可抑制PMN的功能反应,但它们对细胞内钙浓度([Ca2+]i)的影响尚未得到广泛研究。本研究检测了咯利普兰(一种选择性PDE IV抑制剂)对趋化肽甲酰甲硫氨酰亮氨酰苯丙氨酸(fMLP)诱导的、负载有fura-2的人PMN中[Ca2+]i变化的影响。咯利普兰(1 nM - 10 μM)未改变基础[Ca2+]i值。fMLP(10 nM,约为半数有效浓度)产生了短暂的钙反应,即一个峰值后衰减至高于基线的残余值。fMLP刺激后的峰值[Ca2+]i值未改变,但在经咯利普兰(0.1 - 10 μM)处理的细胞中观察到更快的衰减和更低的残余[Ca2+]i。在硫柳汞(20 μM)处理后加入fMLP产生了一个峰值,随后是持续的振荡反应。咯利普兰(高达10 μM)未改变峰值,但抑制了持续反应(-log IC50 = 6.39 ± 0.12)。咯利普兰的抑制作用可能是由于环磷酸腺苷细胞含量增加导致的Ca2+动员改变。SKF94120(一种选择性PDE III抑制剂)对fMLP诱导的钙反应产生轻微影响。SCA40(一种PDE III/IV/V混合抑制剂)产生了类似的效果,但效力低于咯利普兰。钙反应的降低可能是PDE IV抑制剂抑制PMN功能的基础。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验